Jpmorgan Chase & CO Arrowhead Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.27 Trillion
Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 487,671 shares of ARWR stock, worth $7.48 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

487,671

Previous 2,020,426 75.86%

Holding current value

$7.48 Million

Previous $38 Million 83.65%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$12.74 - $21.53 $19.5 Million - $33 Million	-1,532,755 Reduced 75.86%	487,671 $6.21 Million
Q4 2024 Feb 12, 2025	SELL	$17.7 - $26.34 $2.27 Million - $3.37 Million	-127,979 Reduced 5.96%	2,020,426 $38 Million
Q3 2024 Dec 26, 2024	SELL	$19.36 - $29.54 $3.24 Million - $4.94 Million	-167,300 Reduced 7.22%	2,148,405 $41.6 Million
Q3 2024 Nov 08, 2024	SELL	$19.36 - $29.54 $3.24 Million - $4.94 Million	-167,300 Reduced 7.22%	2,148,405 $41.6 Million
Q2 2024 Dec 26, 2024	BUY	$21.87 - $28.24 $3.66 Million - $4.72 Million	167,300 Added 7.79%	2,315,705 $60.2 Million
Q2 2024 Aug 12, 2024	SELL	$21.87 - $28.24 $7.05 Million - $9.1 Million	-322,358 Reduced 12.22%	2,315,705 $60.2 Million
Q1 2024 Dec 26, 2024	BUY	$27.21 - $39.48 $13.3 Million - $19.3 Million	489,658 Added 22.79%	2,638,063 $75.4 Million
Q1 2024 May 10, 2024	SELL	$27.21 - $39.48 $3.07 Million - $4.46 Million	-112,985 Reduced 4.11%	2,638,063 $75.4 Million
Q4 2023 Dec 26, 2024	BUY	$21.2 - $31.03 $12.8 Million - $18.7 Million	602,643 Added 28.05%	2,751,048 $84.2 Million
Q4 2023 Feb 12, 2024	SELL	$21.2 - $31.03 $679,460 - $994,511	-32,050 Reduced 1.15%	2,751,048 $84.2 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $2.56 Million - $3.53 Million	-97,816 Reduced 3.4%	2,783,098 $74.8 Million
Q2 2023 Aug 11, 2023	SELL	$25.16 - $41.38 $730,923 - $1.2 Million	-29,051 Reduced 1.0%	2,880,914 $103 Million
Q1 2023 May 18, 2023	BUY	$23.68 - $38.51 $6.28 Million - $10.2 Million	265,031 Added 10.02%	2,909,965 $73.9 Million
Q1 2023 May 11, 2023	SELL	$23.68 - $38.51 $4.17 Million - $6.77 Million	-175,888 Reduced 6.24%	2,644,934 $67.2 Million
Q4 2022 Feb 13, 2023	SELL	$28.0 - $40.56 $2.01 Million - $2.91 Million	-71,699 Reduced 2.48%	2,820,822 $114 Million
Q3 2022 Nov 14, 2022	SELL	$29.63 - $48.31 $2.91 Million - $4.75 Million	-98,294 Reduced 3.29%	2,892,521 $95.6 Million
Q2 2022 Aug 11, 2022	BUY	$27.79 - $50.61 $1.94 Million - $3.54 Million	69,862 Added 2.39%	2,990,815 $105 Million
Q1 2022 May 11, 2022	SELL	$39.62 - $69.97 $2.3 Million - $4.07 Million	-58,111 Reduced 1.95%	2,920,953 $134 Million
Q4 2021 Feb 10, 2022	BUY	$58.09 - $82.51 $8.12 Million - $11.5 Million	139,822 Added 4.92%	2,979,064 $198 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $166 Million - $241 Million	2,839,242 New	2,839,242 $177 Million

Others Institutions Holding ARWR

# of Institutions

300

Shares Held

95.2M

Call Options Held

306K

Put Options Held

432K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.62B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Arrowhead Pharmaceuticals, Inc. Transaction History